Pro Medicus Ltd (ASX: PME) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Pro Medicus Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Pro Medicus Ltd (ASX: PME)
Latest News
Broker Notes
Top brokers name 3 ASX shares to buy today
Share Market News
5 things to watch on the ASX 200 on Wednesday
Growth Shares
3 roaring ASX shares to hold for the next 20 years
Share Gainers
Here are the top 10 ASX 200 shares today
Value Investing
3 ASX stocks boasting better margins than Nvidia
Investing Strategies
2 ASX 200 shares to buy in the most 'interesting' sector right now
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Guess which are the 2 newest members of the ASX 100 index
Broker Notes
Top brokers name 3 ASX shares to buy next week
Broker Notes
Leading brokers name 3 ASX shares to buy today
Share Gainers
Here are the top 10 ASX 200 shares today
Dividend Investing
25 ASX 200 shares with ex-dividend dates next week
Frequently Asked Questions
-
Yes, the company historically pays two fully franked dividends a year.
-
Pro Medicus generally pays its shareholder dividends in March and October.
-
Pro Medicus Ltd listed on the ASX on 10 October 2000.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
29 Feb 2024 | $0.1800 | 100.00% | Interim | 22 Mar 2024 |
06 Sep 2023 | $0.1700 | 100.00% | Final | 28 Sep 2023 |
02 Mar 2023 | $0.1300 | 100.00% | Interim | 24 Mar 2023 |
08 Sep 2022 | $0.1200 | 100.00% | Final | 30 Sep 2022 |
03 Mar 2022 | $0.1000 | 100.00% | Interim | 25 Mar 2022 |
09 Sep 2021 | $0.0800 | 100.00% | Final | 01 Oct 2021 |
04 Mar 2021 | $0.0700 | 100.00% | Interim | 19 Mar 2021 |
10 Sep 2020 | $0.0600 | 100.00% | Final | 02 Oct 2020 |
05 Mar 2020 | $0.0600 | 100.00% | Interim | 20 Mar 2020 |
12 Sep 2019 | $0.0450 | 100.00% | Final | 04 Oct 2019 |
12 Mar 2019 | $0.0250 | 100.00% | Special Cash | 17 May 2019 |
07 Mar 2019 | $0.0350 | 100.00% | Interim | 22 Mar 2019 |
06 Sep 2018 | $0.0350 | 100.00% | Final | 27 Sep 2018 |
08 Mar 2018 | $0.0250 | 100.00% | Interim | 23 Mar 2018 |
07 Sep 2017 | $0.0000 | 100.00% | Final | 28 Sep 2017 |
08 Sep 2016 | $0.0150 | 0.00% | Final | 29 Sep 2016 |
10 Mar 2016 | $0.0150 | 0.00% | Interim | 24 Mar 2016 |
15 Mar 2006 | $0.0050 | 100.00% | Special | 05 Apr 2006 |
15 Mar 2006 | $0.0200 | 100.00% | Interim | 05 Apr 2006 |
14 Sep 2005 | $0.0050 | 100.00% | Special Cash | 04 Oct 2005 |
14 Sep 2005 | $0.0275 | 100.00% | Final | 04 Oct 2005 |
16 Mar 2004 | $0.0125 | 100.00% | Interim | 05 Apr 2004 |
PME ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Pro Medicus Ltd
Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.
Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.
Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.
PME Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
18 Apr 2024 | $102.09 | $1.91 | 1.91% | 393,275 | $99.30 | $102.17 | $99.30 |
17 Apr 2024 | $100.18 | $-1.82 | -1.78% | 401,089 | $103.59 | $104.19 | $98.81 |
16 Apr 2024 | $102.00 | $-4.35 | -4.09% | 489,887 | $105.27 | $106.52 | $102.00 |
15 Apr 2024 | $106.35 | $-1.14 | -1.06% | 243,734 | $106.00 | $106.93 | $104.85 |
12 Apr 2024 | $107.49 | $-0.51 | -0.47% | 217,770 | $108.00 | $108.97 | $106.87 |
11 Apr 2024 | $108.00 | $-1.80 | -1.64% | 298,895 | $108.72 | $109.80 | $104.66 |
10 Apr 2024 | $109.80 | $-0.18 | -0.16% | 240,385 | $110.20 | $111.70 | $109.80 |
09 Apr 2024 | $109.98 | $1.80 | 1.66% | 192,757 | $106.92 | $110.27 | $106.77 |
08 Apr 2024 | $108.18 | $3.20 | 3.05% | 291,435 | $106.39 | $109.00 | $105.96 |
05 Apr 2024 | $104.98 | $0.43 | 0.41% | 295,294 | $104.68 | $108.52 | $104.55 |
04 Apr 2024 | $104.55 | $2.70 | 2.65% | 349,159 | $102.64 | $105.22 | $102.47 |
03 Apr 2024 | $101.85 | $-3.15 | -3.00% | 363,582 | $102.10 | $102.40 | $97.33 |
02 Apr 2024 | $105.00 | $1.25 | 1.20% | 357,010 | $103.75 | $106.44 | $103.00 |
28 Mar 2024 | $103.75 | $1.21 | 1.18% | 202,397 | $102.28 | $103.89 | $101.59 |
27 Mar 2024 | $102.54 | $1.87 | 1.86% | 287,245 | $101.36 | $103.06 | $101.27 |
26 Mar 2024 | $100.67 | $0.77 | 0.77% | 355,968 | $98.66 | $101.49 | $98.23 |
25 Mar 2024 | $99.90 | $3.70 | 3.85% | 262,041 | $96.07 | $99.90 | $95.70 |
22 Mar 2024 | $96.20 | $-0.26 | -0.27% | 282,756 | $96.19 | $96.82 | $95.57 |
21 Mar 2024 | $96.46 | $0.44 | 0.46% | 344,845 | $95.95 | $97.00 | $95.56 |
20 Mar 2024 | $96.02 | $-1.09 | -1.12% | 248,302 | $97.45 | $97.68 | $96.00 |
19 Mar 2024 | $97.11 | $-2.31 | -2.32% | 462,859 | $99.11 | $99.19 | $96.50 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
21 Feb 2024 | Alice Williams | Buy | 850 | $74,681 |
On-market trade.
|
16 Feb 2024 | Alice Williams | Buy | 810 | $72,875 |
On-market trade.
|
27 Nov 2023 | Alice Williams | Buy | 250 | $22,510 |
On-market trade.
|
21 Nov 2023 | Anthony Hall | Sell | 1,000,000 | $88,020,000 |
On-market trade.
|
21 Nov 2023 | Sam Hupert | Sell | 1,000,000 | $88,020,000 |
On-market trade.
|
25 Aug 2023 | Anthony Hall | Transfer | 70,000 | $5,030,200 |
Off-market transfer. non-cash, Estimated value
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Sam Aaron Hupert | Chief Executive OfficerManaging Director | Oct 2007 |
Dr Hupert served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
|
Mr Anthony Barry Hall | Executive DirectorTechnology Director | Jan 1983 |
Mr Hall has been principal architect and developer of the core software systems.
|
Mr Peter Terence Kempen | Non-Executive ChairmanNon-Executive Director | Mar 2008 |
Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda's College Ltd, University of Melbourne. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst and Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honours.
|
Ms Alice Joan Morrice Williams | Non-Executive Director | Sep 2021 |
Ms Williams is also a non-executive director of Vocus Group, Djerriwarrh Investments, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit and Risk Committee of Djerriwarrh Investments, ASC and Vocus Group and is a member of the Audit and Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Non-Executive member of the Foreign Investment Review Board. She is Chair of Risk committee and also serves on the People and Culture committee.
|
Ms Deena Robyn Shiff | Non-Executive Director | Aug 2020 |
Ms Shiff is also Chair of the Supervisory Board of Marley Spoon AG and is an Independent Member of the board of the Global Alliance for Vaccines and Immunisation, the multi-lateral global health fund based in Geneva. Deena is also on the board of Opera Australia. Previous board roles include Chairman of the global board of BAI Communications, Non-Executive Director of Appen, EOS Holdings and Director of the Citadel Group, Vice Chairman of the Government's Export Credit Agency EFIC, as well as board roles in several venture capital backed growth stage ICT companies. She is Chair of the People and Culture committee and serves on the Risk committee.
|
Mr Anthony James Glenning | Non-Executive Director | May 2016 |
Mr Glenning is the fund manager of Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. He is a Director of Austco Healthcare since September 2018, an international provider of healthcare communication and clinical workflow management solutions. Anthony is also a Director of Iress since October 2022, a technology company providing software to the financial services industry. Anthony has previously been Chairman of Cyrise Pty Ltd, an accelerator for early-stage cyber security start-ups and Investment Director of Starfish Ventures and was the founder and previously the CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He also serves on the People and Culture committee and Risk committee.
|
Dr Leigh Bernard Farrell | Non-Executive Director | Sep 2017 |
Dr Farrell is the Head of Health Security Systems Australia, a Division of DMTC, Managing Director of AdNED Pty, non-executive director of both Ena Respiratory Pty and Axelia Oncology Pty, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee, a member of the Independent Advisory Council of Medicines Australia, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins, Chair of the Scientific Advisory Board of Island Pharmaceuticals Ltd and is a member of the National Measurement Institute Mask Testing Forum. Leigh was previously Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. She also serves on the People and Culture committee and Risk committee.
|
Ms Danny English | Company Secretary | Mar 2023 |
-
|
Clayton Hatch | Chief Financial Officer |
-
|
|
Nick Peace | Chief Strategy Officer |
-
|
|
Danny English | Company Secretary |
-
|
|
Danny Tauber | General Manager Australia |
-
|
|
Malte Westerhoff | General Manager Europe and Global Chief Technology Officer |
-
|
|
Brad Levin | General Manager North America and Global Head of Marketing |
-
|
|
Teresa Gschwind | Global Head of Customer Service |
-
|
|
Sean Lambright | Global Head of Sales |
-
|
|
Sharni Redenbach | People and Culture Director |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Dr S Hupert (multiple shareholdings) | 26,137,660 | 25.03% |
Mr A Hall (multiple shareholdings) | 26,109,000 | 25.00% |
HSBC Custody Nominees (Australia) Limited | 15,568,938 | 14.91% |
J P Morgan Nominees Australia Limited | 7,320,773 | 7.01% |
Citicorp Nominees Pty Ltd | 6,911,271 | 6.62% |
National Nominees Limited | 1,951,517 | 1.87% |
BNP Paribas Noms Pty Ltd | 1,247,848 | 1.19% |
Mr Peter Terence Kempen and Mrs Elaine Margaret Kempen (multiple shareholdings) | 629,082 | 0.60% |
Citicorp Nominees (Colonial First State) | 605,943 | 0.58% |
Mr Bram Vander Jagt and Mrs Maaike Vander Jagt | 480,000 | 0.46% |
Grain Exporters (Australia) Pty Ltd | 479,000 | 0.46% |
Mr Michael Wu | 429,244 | 0.41% |
Mr Danny Tauber | 290,876 | 0.28% |
Mr Stephen Geoffrey Wilson and Ms Denise Adele Prandi | 285,037 | 0.27% |
Mr Colin Gregory Organ | 271,000 | 0.26% |
Mr John Charles Plummer | 250,000 | 0.24% |
Mr Kenneth John Vander Jagt and Mrs Tanya Vander Jagt | 208,159 | 0.20% |
Mr Roderick Lyle | 190,000 | 0.18% |
Mr Sean Michael Lambright | 179,039 | 0.17% |
Mr Evan Philip Clucas and Ms Leanne Jane Weston | 158,980 | 0.15% |